article thumbnail

HDA 2023 Traceability Seminar: An FDA DSCSA Overview

Pharmaceutical Commerce

Event’s first session aims to analyze the legislation’s implementation, as FDA enforcement is delayed until November 2024.

FDA 106
article thumbnail

HDA 2024 Traceability Seminar: An FDA Perspective on DSCSA

Pharmaceutical Commerce

The agency provides an update surrounding the Act’s implementation efforts.

FDA 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HDA 2024 Traceability Seminar: What to Expect From FDA Inspections

Pharmaceutical Commerce

In an interview with Pharma Commerce Editor Nicholas Saraceno, Jeb Hunter, Senior Regulatory Consultant, EAS Consulting Group, discusses the on “What to Expect When They’re Inspecting: FDA Inspections on DSCSA Compliance" breakout session at the 2024 HDA Traceability Seminar.

FDA 59
article thumbnail

“Thaw Out” with Pharma Thought Leaders at the 2024 Puerto Rico Pharmaceutical Summit: HPM Directors to Discuss Drug Approvals and Puerto Rico “Exportation” Best Practices

The FDA Law Blog

This day-long (FREE) seminar is a must-attend event for anyone in the pharmaceutical sector interested in understanding the “ins and outs” of doing business in the Territory, as well as an opportunity to interact with those who already have a keen understanding of doing business in Puerto Rico.

article thumbnail

Clinical decision-making insights for haematologists and oncologists

pharmaphorum

All this comes at a time when COVID-19 has made attending medical conferences and seminars in person impractical because of social distancing regulations. Mohty said: “I think the Medscape FDA results are a wonderful example of how you can positively impact a given field, and I think we should really move in this direction.”.

FDA 105
article thumbnail

International Collaboration and Reliance: Regulatory Panel Discussion at the 2022 ISPE Singapore Conference

ISPE

It was usual practice for TGA to prepare additional guidance/explanatory documents for industry and for TGA inspection staff to participate in training seminars to assist industry. The outcomes of these inspections were shared extensively with MRA partners such as EMA and US FDA. Canada DHPID ). Canada DHPID ).

FDA 97
article thumbnail

Regulatory Panel Discussion on International Collaboration and Reliance

ISPE

It was usual practice for TGA to prepare additional guidance/explanatory documents for industry and for TGA inspection staff to participate in training seminars to assist industry. The outcomes of these inspections were shared extensively with MRA partners such as EMA and US FDA. The approach by TGA and HSA were very similar.

FDA 52